Cellectar Biosciences, Inc. CLRB
1.80
(0.28)
(13.46%)
as of 25 Sep
- Market cap
- $19.6M
- P/E
- 0.0×
Follow CLRB
Insider Buys
alert about insiders buying in the last 12 month
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
7.47 | 4.95 | 8.60 | 4.11 | 16.26 | 9.16 | 1.78 | 0.41 | 2.58 | 2.96 |
Net Debt/EBITDA |
1.26 | 0.83 | 1.15 | 0.73 | 3.75 | 1.48 | 0.67 | 0.25 | 0.45 | 0.58 |
Debt/Assets |
0.03% | 0.02% | 0.00% | 3.44% | 0.51% | 0.45% | 2.56% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.05 | 0.01 | 0.01 | 0.07 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.88 | 0.73 | 0.74 | 0.83 | 0.92 | 0.94 | 0.79 | 0.76 | 1.07 | 1.06 |
Capex/Depreciation |
(0.20) | (0.22) | (0.19) | (0.18) | (0.44) | (0.94) | (1.52) | (4.49) | (0.36) | (0.03) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (130.69%) | (133.83%) | (151.08%) | (151.16%) | (70.75%) | (72.63%) | (159.70%) | 732.16% | 1,470.68% | (200.01%) | |
| (81.67%) | (106.48%) | (110.87%) | (103.23%) | (42.57%) | (50.33%) | (108.15%) | (254.09%) | (237.45%) | (107.74%) | |
ROIC |
(288.74%) | (1,222.58%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(77.97%) | (174.48%) | (120.26%) | (155.71%) | (27.58%) | (73.26%) | (336.55%) | 309.60% | (285.42%) | (221.49%) |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.11 | 0.13 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(5,569.67) | (2,418.51) | (1,189.10) | (457.74) | (212.05) | (122.82) | (108.29) | (81.67) | (39.07) | (8.87) |
Cash per Share |
7,666.40 | 2,140.72 | 1,344.51 | 414.64 | 866.14 | 193.10 | 84.54 | 23.50 | 19.08 | 5.06 |
Shareholders Equity per Share |
9,026.60 | 2,288.19 | 1,339.49 | 353.88 | 830.22 | 178.72 | 34.69 | (37.25) | 11.71 | 3.27 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
9,026.60 | 2,288.19 | 1,339.49 | 353.88 | 830.22 | 178.72 | 34.69 | (37.25) | 11.71 | 3.27 |
Free Cash Flow |
(8.35) | (11.37) | (11.77) | (11.72) | (14.00) | (22.71) | (25.45) | (33.24) | (47.69) | (23.12) |
Working Capital |
10.56 | 8.36 | 12.33 | 8.62 | 54.38 | 32.58 | 9.03 | (14.91) | 14.86 | 9.29 |
Capital Expenditures |
(0.07) | (0.35) | (0.33) | (0.02) | (0.06) | (0.14) | (0.23) | (0.86) | (0.10) | (0.01) |
Net Current Asset Value |
10.41 | 8.36 | 12.16 | 8.19 | 54.08 | 32.41 | 7.09 | (16.78) | 13.07 | 7.60 |
| Other line items | ||||||||||
Quick Ratio |
7.04 | 4.76 | 8.21 | 3.83 | 16.04 | 8.95 | 1.73 | 0.38 | 2.48 | 2.78 |
Depreciation/Fixed assets |
0.25 | 6.32 | 3.24 | 0.31 | 0.40 | 0.44 | 0.35 | 0.18 | 0.39 | 0.39 |
Cash ROIC |
(38.84%) | (54.11%) | (45.11%) | (60.36%) | (12.73%) | (33.25%) | (89.74%) | 598.27% | (128.62%) | (108.90%) |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(5,521.47) | (2,344.74) | (1,155.77) | (456.79) | (211.10) | (122.06) | (107.33) | (79.55) | (38.98) | (8.86) |
Capex per Share |
(48.20) | (73.77) | (33.33) | (0.96) | (0.95) | (0.76) | (0.96) | (2.12) | (0.09) | 0.00 |
Average Payables |
1.05 | 1.64 | 1.71 | 2.10 | 3.05 | 3.65 | 4.67 | 7.33 | 8.38 | 6.00 |
Average Assets |
11.46 | 14.10 | 13.96 | 13.65 | 35.46 | 47.93 | 29.40 | 16.83 | 18.77 | 20.23 |
Average Common Equity |
7.16 | 11.22 | 10.25 | 9.32 | 21.33 | 33.21 | 19.91 | (5.84) | (3.03) | 10.90 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates